Synthego

In Jan 2017, Synthego had secured $41 million in funding from investors including, Jennifer A. Doudna, 8VC, and Founders Fund. Recently, in October 2018, it raise another $110 million in Series C funding round. The round was led by Founders Fund, with additional investment from existing investors 8VC and Menlo Ventures. Synthego's total funding is about $160 million.

Synthego has disclosed $49.5m in funding by 8VC, Intel Capital, Founders Fund, Menlo Ventures, AME Cloud Ventures, and Jennifer Doudna.

Synthego is a privately held, genome engineering innovation company headquartered in California. It focuses on providing broader access to CRIPR to accelerate basic scientific discovery, research cures for diseases, and develop novel synthetic biology applications through the company's automated, full stack genome engineering platform.

The company's product portfolio is divided into two areas: engineered cells and CRISPR kits. Under the engineered cells, Synthego offers knockout cell pools, knockout cell clone, and advanced cells with the client's custom edits. Under the CRISPR kits, it offers synthetic sgRNA kits, gene knockout kits, CRISPR screening libraries, advanced RNA, and synthetic cr:tracrRNA kits.

In Jan 2017, Synthego had secured $41 million in funding from investors including, Jennifer A. Doudna, 8VC, and Founders Fund. Recently, in October 2018, it raise another $110 million in Series C funding round. The round was led by Founders Fund, with additional investment from existing investors 8VC and Menlo Ventures. Synthego's total funding is about $160 million.